Please login to the form below

Not currently logged in
Email:
Password:

New Molecular Entities

This page shows the latest New Molecular Entities news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

Barron made much of GSK’s immunology and immuno-oncology portfolio on the company’s interim results call, saying it has 27 new molecular entities (NMEs) in these areas which account ... Meanwhile, vaccines grew 12% to £1.92bn led by new shingles

Latest news

  • GSK: we won’t be splitting up any time soon

    The company has 27 immunomodulatory new molecular entities (NME) in clinical trials, around 60% of its total clinical pipeline. ... Also announced was a major new alliance with consumer gene testing company 23andMe.

  • Pharma is ‘getting lower returns on R&D’ Pharma is ‘getting lower returns on R&D’

    Deloitte also welcomes an increase in the number of approvals of new molecular entities, orphan drugs and break/fast-tracked therapies which its says “leads us to present an overall optimistic ... with new ways of engaging patients in clinical trials

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    Sanofi said in a preview of the event this morning that its pipeline currently has 71 projects, including 37 new molecular entities and novel vaccines, with nine potential marketing applications in

  • ICON boosts leadership teams ICON boosts leadership teams

    Pharmaceutical service provider ICON has boosted its scientific operations, medical imaging and real world evidence leadership teams with three new senior appointments. ... Most recently, Dr McCracken led the Imaging Centre of Excellence at Eisai, having

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    The new CDF started operating at the end of July, with four new cancer drugs made available under the scheme. ... We have made five cancer medicines available to UK patients in the last three years and have 70 new molecular entities in our pipeline but,

More from news
Approximately 2 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... The company generates

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    Despite the new schemes, healthcare in China is still considered expensive, with out-ofpocket payments commonly high. ... Conversely, however, Brazil's uptake of New Molecular Entities (NMEs) between 2006-2010 was the highest of the BRIC nations – with

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Chancellor Merkel has proposed a new system of financial regulation within the EU. ... Source: EFPIA, 2009. According to Vfa in 2010 only 26 new molecular entities were launched in the German market, compared to 36 in 2009.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    Gaweco will lead Apeiron’s immuno-oncology programmes, overseeing the discovery, clinical and medical functions of the company’s new molecular entities pipeline of cancer immunotherapies. ... class new treatments for cancer patients and to help

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

A reflection of ESMO
Client Relationship Director Fabienne Wild from Ashfield Meetings & Events reflects on the recent conference season and on her experience at the European Society for Medical Oncology (ESMO)....
OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....

Infographics